Regencell Bioscience Holdings Ltd Stock Price, News & Analysis

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results of the EARTH-B Trial, demonstrating the efficacy of its oral COVID-19 treatment, RGC-COV19^TM. Conducted on 51 patients in Malaysia, the trial showed that 94.1% of participants experienced complete symptom elimination within six days. Notably, 90.2% reported symptom improvement after one dose. No severe adverse effects were noted, and treatment did not lead to hospitalizations or deaths. These findings reinforce the potential of RGC-COV19^TM as a promising alternative treatment for COVID-19.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced that Chairman and CEO Yat-Gai Au purchased $5.03 million worth of Ordinary Shares, increasing his ownership to 81% of the company. Au criticized short-selling tactics affecting the company and pledged to maintain a $1 annual salary until a $1 billion market capitalization is achieved. He also initiated a philanthropic project aiding children with ADHD, ASD, and COVID-19. Directors and employees have committed to a six-month lock-up for their stock options post-vesting, effective from July 16, 2022.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced that CEO Yat-Gai Au purchased $5.03 million in Ordinary Shares, increasing his ownership to 81% of the total shares. Au criticized short-selling tactics impacting the company's stock, pledging a $1 annual salary until market capitalization reaches $1 billion. Additionally, all directors and employees agreed to a six-month lock-up for their stock options post-vesting. Au plans to fund grants for over 10,000 children with ADHD and ASD, having already aided 150. The company's focus is on Traditional Chinese Medicine for neurocognitive disorders and COVID-19 treatments.

Regencell Bioscience Holdings Limited recently participated in a video interview with SNN Network, discussing their focus on Traditional Chinese Medicine (TCM) for treating neurocognitive disorders like ADHD and ASD, as well as infectious diseases. The company aims to launch three standardized TCM formulas for varying severities of ADHD and ASD patients, starting in Hong Kong. Additionally, they plan to provide COVID-related treatments in ASEAN countries, India, Japan, Australia, and New Zealand. The interview is available on their official website.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced positive results from its EARTH efficacy trial evaluating RGC-COV19^TM, a COVID-19 treatment. Of the 37 patients, 97.3% eliminated all symptoms, except for sensory dysfunction and occasional cough, within six days. Notably, 83.8% experienced symptom relief after just one dose. The trial indicated no adverse side effects, and no patients were hospitalized or died during the study. These findings highlight the potential of RGC-COV19^TM for broader COVID-19 treatment applications.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) has appointed Dr. William Wing-Yan Lo to its Board of Directors, effective immediately. This move fills a vacancy following a prior director's resignation and aims to strengthen the board. Dr. Lo, with over 30 years of experience in biopharma and corporate governance, will chair the audit committee and serve on the compensation and nomination committees. He previously held senior roles in several reputable companies and currently advises multiple public companies. Regencell focuses on TCM for neurocognitive disorders and infectious diseases.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the purchase of Ordinary Shares totaling $1,125,807 by CEO Yat-Gai Au, who now owns 80.15% of the company's shares. The purchases, made through a Rule 10b-18 Plan, reflect Au's confidence in Regencell's strategy to lead in treatments for ADHD, ASD, and infectious diseases like COVID-19. Regencell focuses on traditional Chinese medicine for neurocognitive disorders and has plans for future share purchases. However, certain shares are subject to lock-up restrictions.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the addition of its shares to the MSCI World Micro Cap Index effective December 1, 2021. This decision, made public on November 11, 2021, reflects Regencell's growing recognition within the investment community. The MSCI World Micro Cap Index includes 6,192 constituents and covers around 1% of the free float-adjusted market capitalization across 23 developed countries. CEO Yat-Gai Au expressed optimism that this milestone will boost the company's visibility among institutional investors.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) has announced a joint venture with Honor Epic Enterprises to provide Traditional Chinese Medicine (TCM) treatments for COVID-19 in several regions including ASEAN countries, India, Japan, Australia, and New Zealand. Regencell will own 60% of the venture. Initial treatments have shown improvements in 12 COVID patients after about 5 days. While the research is ongoing, the company highlights potential risks and uncertainties surrounding the treatment's commercialization.